19194-96-8

Basic information

• Product Name: methyl 6-methoxypyridazine-3-carboxylate
• Synonyms: 6-Methoxypyridazine-3-carboxylic acid methyl ester;3-Pyridazinecarboxylic acid, 6-methoxy-, methyl ester
• CAS NO: 19194-96-8
• Molecular Formula: C₇H₈N₂O₃
• Molecular Weight: 168.15
• Mol File: 19194-96-8.mol
• Article Data: 10

Chemical Properties

• Melting Point: 119-120 °C(Solv: ethyl ether (60-29-7))
• Boiling Point: 341.848°C at 760 mmHg
• Flash Point: 160.544°C
• Density: 1.22g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.505
• PKA: 1.16±0.10(Predicted)
• CAS DataBase Reference: methyl 6-methoxypyridazine-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 6-methoxypyridazine-3-carboxylate(19194-96-8)
• EPA Substance Registry System: methyl 6-methoxypyridazine-3-carboxylate(19194-96-8)

Safety Data

• Hazardous Substances Data: 19194-96-8(Hazardous Substances Data)

Upstream product

• 124-41-4 sodium methylate 
• 65202-50-8 methyl 6-chloro-3-pyridazinecarboxylate 
• 56434-28-7 6-methoxypyridazine-3-carboxylic acid 
• 1722-10-7 3-chloro-6-methoxypyridazine 
• 67-56-1 methanol 
• 152327-57-6 dimethyl (E)-3-diazo-1-propene-1,3-carboxylate 
• 1154750-66-9 trans-4-[tris(dimethylamino)phosphoranylidene]azinopent-2-endioic acid dimethyl ester 
• 6531-04-0 6-chloro-pyridazine-3-carbonyl chloride 
• 5096-73-1 6-chloro-pyridazine-3-carboxylic acid 
• 201230-82-2 carbon monoxide 
• 37972-69-3 6-oxo-1,6-dihydropyridazine-3-carboxylic acid 
• 77-78-1 dimethyl sulfate 

Downstream Products

• 63001-30-9 methyl 6‐oxo‐1,6‐dihydropyridazine‐3‐carboxylate 
• 1591827-28-9 3-chloro-5-((4-methyl-6-oxo-1-((6-oxo-1-(tetrahydro-2H-pyran-2-yl)-1,6-dihydro pyridazin-3-yl)methyl)-1,6-dihydropyrimidin-5-yl)oxy)benzonitrile 
• 1591823-78-7 3-chloro-5-((6-oxo-1-((6-oxo-1,6-dihydropyridazin-3-yl)methyl)-4-(trifluoromethyl)-1,6-dihydropyrimidin-5-yl)oxy)benzonitrile 
• 1591823-96-9 3-chloro-5-((4-methyl-6-oxo-1-((6-oxo-1,6-dihydropyridazin-3-yl)methyl)-1,6-dihydropyrimidin-5-yl)oxy)benzonitrile 
• 1591827-39-2 methyl 5-bromo-1-(4-methoxybenzyl)-6-oxo-1,6-dihydropyridazine-3-carboxylate 
• 1591827-40-5 4-bromo-6-(hydroxymethyl)-2-(4-methoxybenzyl)pyridazin-3(2H)-one 
• 1591827-41-6 (5-bromo-1-(4-methoxybenzyl)-6-oxo-1,6-dihydropyridazin-3-yl)methyl methanesulfonate 
• 1591827-42-7 3-((1-((5-bromo-1-(4-methoxybenzyl)-6-oxo-1,6-dihydropyridazin-3-yl)methyl)-6-oxo-4-(trifluoromethyl)-1,6-dihydropyrimidin-5-yl)oxy)-5-chlorobenzonitrile 
• 1591827-43-8 3-chloro-5-((1-((1-(4-methoxybenzyl)-6-oxo-5-phenyl-1,6-dihydropyridazin-3-yl)methyl)-6-oxo-4-(trifluoromethyl)-1,6-dihydropyrimidin-5-yl)oxy)benzonitrile 
• 1591824-21-3 3-chloro-5-((6-oxo-1-((6-oxo-5-phenyl-1,6-dihydropyridazin-3-yl)methyl)-4-(trifluoro methyl)-1,6-dihydropyrimidin-5-yl)oxy)benzonitrile 
• 1591827-50-7 3-chloro-5-((1-((5-(6-fluoropyridin-3-yl)-1-(4-methoxybenzyl)-6-oxo-1,6-dihydropyridazin-3-yl)methyl)-6-oxo-4-(trifluoromethyl)-1,6-dihydropyrimidin-5-yl)oxy)benzonitrile 
• 1591825-45-4 3-chloro-5-((1-((5-(6-fluoropyridin-3-yl)-6-oxo-1,6-dihydropyridazin-3-yl)methyl)-6-oxo-4-(trifluoromethyl)-1,6-dihydropyrimidin-5-yl)oxy)benzonitrile 
• 1591827-53-0 methyl 5-chloro-1-(4-methoxybenzyl)-6-oxo-1,6-dihydropyridazine-3-carboxylate 
• 1591827-54-1 3-chloro-5-((1-((1-(4-methoxybenzyl)-6-oxo-5-(1H-pyrazol-1-yl)-1,6-dihydropyridazin-3-yl)methyl)-6-oxo-4-(trifluoromethyl)-1,6-dihydropyrimidin-5-yl)oxy)benzonitrile 

Relevant articles and documents

Stereochemical aspect of the intramolecular diaza-wittig reaction

-

PYRIDAZINE COMPOUND

The present provides a pyridazine compound having an inhibiting effect on Stearoyl-CoA desaturase (SCD) (in particular, SCD1). The present provides a compound represented by formula (where each symbol is as defined as in the Specification) or a salt thereof

TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF

The present invention is directed to substituted five membered heteroaryl benzamide compounds compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.